CLINICAL AND ECONOMIC IMPLICATIONS OF USING NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR NON-VALVULAR ATRIAL FIBRILLATION USING AVAILABLE EVIDENCE FROM REAL-WORLD EXPERIENCE